The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.
The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.
Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...
Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...
Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...
It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...
The Global Fund to fight AIDS, TB and Malaria and the US President’s Emergency Plan for AIDS Relief (PEPFAR) recently ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Medicines and Healthcare products Regulatory Agency has approved the medicine seladelpar in adults for the treatment of a liver illness ...
With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...